Kevin M. Friedman

2.4k total citations
15 papers, 530 citations indexed

About

Kevin M. Friedman is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Kevin M. Friedman has authored 15 papers receiving a total of 530 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Kevin M. Friedman's work include CAR-T cell therapy research (13 papers), Immune Cell Function and Interaction (5 papers) and Immunotherapy and Immune Responses (3 papers). Kevin M. Friedman is often cited by papers focused on CAR-T cell therapy research (13 papers), Immune Cell Function and Interaction (5 papers) and Immunotherapy and Immune Responses (3 papers). Kevin M. Friedman collaborates with scholars based in United States, Australia and Germany. Kevin M. Friedman's co-authors include Christopher Horvath, Holly M. Horton, Tracy E. Garrett, Mikayel Mkrtichyan, Samir N. Khleif, Rasha Abu Eid, John Evans, Richard A. Morgan, Raed Samara and Maher Y. Abdalla and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Kevin M. Friedman

15 papers receiving 522 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kevin M. Friedman United States 8 405 283 193 67 57 15 530
Tamara Laskowski United States 7 395 1.0× 403 1.4× 201 1.0× 46 0.7× 90 1.6× 8 645
Kathryn Ruisaard United States 9 324 0.8× 272 1.0× 160 0.8× 77 1.1× 43 0.8× 16 507
Anniek B. van der Waart Netherlands 13 360 0.9× 458 1.6× 150 0.8× 98 1.5× 41 0.7× 22 638
Liora M. Schultz United States 10 347 0.9× 202 0.7× 132 0.7× 50 0.7× 73 1.3× 41 455
Andrea V. Lopez United States 8 503 1.2× 229 0.8× 204 1.1× 63 0.9× 151 2.6× 10 586
Sarah Oelsner Germany 8 651 1.6× 601 2.1× 125 0.6× 55 0.8× 76 1.3× 8 758
Alexander Biederstädt Germany 5 375 0.9× 402 1.4× 155 0.8× 49 0.7× 81 1.4× 9 604
Antonio Valeri Spain 12 294 0.7× 303 1.1× 124 0.6× 96 1.4× 28 0.5× 23 462
Sascha Haubner Germany 9 393 1.0× 263 0.9× 207 1.1× 197 2.9× 50 0.9× 16 614
James Dongjoo Ham United States 6 643 1.6× 550 1.9× 210 1.1× 53 0.8× 132 2.3× 9 832

Countries citing papers authored by Kevin M. Friedman

Since Specialization
Citations

This map shows the geographic impact of Kevin M. Friedman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin M. Friedman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin M. Friedman more than expected).

Fields of papers citing papers by Kevin M. Friedman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin M. Friedman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin M. Friedman. The network helps show where Kevin M. Friedman may publish in the future.

Co-authorship network of co-authors of Kevin M. Friedman

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin M. Friedman. A scholar is included among the top collaborators of Kevin M. Friedman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin M. Friedman. Kevin M. Friedman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Scharenberg, Andrew M., Kevin M. Friedman, Lin T. Guey, et al.. (2025). In vivo chimeric antigen receptor (CAR)-T cell therapy. Nature Reviews Drug Discovery. 25(2). 116–137. 4 indexed citations
2.
3.
Friedman, Kevin M., Tracy E. Garrett, John Evans, et al.. (2018). Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells. Human Gene Therapy. 29(5). 585–601. 166 indexed citations
4.
5.
6.
Grande, Shannon, Molly Perkins, Holly M. Horton, et al.. (2016). Abstract 2296: Inhibition of the PI3K/Akt pathway during CAR T cell production results in enhanced efficacy across multiple in vivo tumor models. Cancer Research. 76(14_Supplement). 2296–2296. 1 indexed citations
7.
Eid, Rasha Abu, Kevin M. Friedman, Mikayel Mkrtichyan, et al.. (2015). Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8+T-cell proliferation and survival. OncoImmunology. 4(5). e1005448–e1005448. 43 indexed citations
8.
Garrett, Tracy E., John Evans, Holly M. Horton, et al.. (2015). A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity. Journal for ImmunoTherapy of Cancer. 3(S2). 4 indexed citations
9.
Horton, Holly M., Tracy E. Garrett, John Evans, et al.. (2015). A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances. Blood. 126(23). 3094–3094. 7 indexed citations
10.
Perkins, Molly, Shannon Grande, Holly M. Horton, et al.. (2015). Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells. Blood. 126(23). 1893–1893. 23 indexed citations
11.
Eid, Rasha Abu, Raed Samara, Laurent Ozbun, et al.. (2014). Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway. Cancer Immunology Research. 2(11). 1080–1089. 126 indexed citations
12.
Friedman, Kevin M., Peter A. Prieto, Colin Gross, et al.. (2012). Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes. Journal of Immunotherapy. 35(5). 400–408. 81 indexed citations
13.
Friedman, Kevin M., et al.. (2011). Augmented Lymphocyte Expansion from Solid Tumors With Engineered Cells for Costimulatory Enhancement. Journal of Immunotherapy. 34(9). 651–661. 17 indexed citations
14.
Hardin, E., Anne C. Pavlick, Leonard Liebes, et al.. (2006). A phase II trial of BAY 43–9006 in metastatic melanoma with molecularly characterized B-Raf status. Journal of Clinical Oncology. 24(18_suppl). 8046–8046. 2 indexed citations
15.
Tokarz, Sara, Catherine Berset, Kevin M. Friedman, et al.. (2004). The ISG15 Isopeptidase UBP43 Is Regulated by Proteolysis via the SCFSkp2 Ubiquitin Ligase. Journal of Biological Chemistry. 279(45). 46424–46430. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tamara Laskowski Breakdown of academic impact, for papers by Kathryn Ruisaard Breakdown of academic impact, for papers by Anniek B. van der Waart Breakdown of academic impact, for papers by Liora M. Schultz Breakdown of academic impact, for papers by Andrea V. Lopez Breakdown of academic impact, for papers by Sarah Oelsner Breakdown of academic impact, for papers by Alexander Biederstädt Breakdown of academic impact, for papers by Antonio Valeri Breakdown of academic impact, for papers by Sascha Haubner Breakdown of academic impact, for papers by James Dongjoo Ham
Rankless by CCL
2026